Results 141 to 150 of about 88,988 (279)

Macular edema after pars plana vitrectomy for primary rhegmatogenous retinal detachment: Incidence, morphology, and risk factors

open access: yesOman Journal of Ophthalmology
PURPOSE: To study the incidence, morphology, and factors affecting macular edema after pars plana vitrectomy (PPV) for primary rhegmatogenous retinal detachment (RRD). STUDY DESIGN: Retrospective study. MATERIALS AND METHODS: The study was conducted at a
D. S. Hamsa   +3 more
doaj   +1 more source

Association Between Vitamin D Deficiency and the Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes: A Meta‐Analysis

open access: yesMolecular Genetics &Genomic Medicine, Volume 14, Issue 1, January 2026.
Meta‐analysis of 20 studies (N = 22,408 T2DM patients). Vitamin D deficiency (25[OH]D < 20 ng/mL) associated with 17% higher DR risk: Pooled OR = 1.17, 95% CI: 1.08–1.27, p < 0.001. Mechanistic link: vitamin D regulates retinal inflammation, VEGF suppression, and endothelial protection.
Guoxiao Yu   +3 more
wiley   +1 more source

The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system

open access: yesBrain Pathology, Volume 36, Issue 1, January 2026.
Sphingolipids are vital components of cell membranes. Metabolic disruptions of sphingolipids, including ceramide and sphingosine‐1‐phosphate, are linked to neurological disorders. This article summarizes the classification, structure, and metabolic processes of sphingolipids, and the physiological and pathological effects of sphingolipid metabolism and
Tian Li   +7 more
wiley   +1 more source

Visual improvement after long-term success of pancreatic transplantation [PDF]

open access: yes, 1990
Andreas G. Tzakis   +6 more
core   +1 more source

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 728-740, January 2026.
Abstract Aims This study aimed to evaluate the efficacy and safety of triple therapy with lobeglitazone 0.5 mg as an add‐on treatment compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.
Da Hea Seo   +8 more
wiley   +1 more source

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent Dose

open access: yesHemodialysis International, Volume 30, Issue 1, Page 80-100, January 2026.
ABSTRACT Introduction Erythropoiesis‐stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)–related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies ...
Alan Jardine   +9 more
wiley   +1 more source

Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema

open access: yesClinical Ophthalmology, 2011
Francesco Bandello1, Umberto De Benedetto1, Karl Anders Knutsson1, Maurizio Battaglia Parodi1, Maria Lucia Cascavilla1, Pierluigi Iacono21Department of Ophthalmology, University Vita-salute, Scientific Institute San Raffaele, Milan, Italy; 2Fondazione G ...
Bandello F   +5 more
doaj  

Extracellular Vesicle‐Derived microRNAs as Fluid Biomarkers in Neurodegenerative Diseases: A Systematic Review

open access: yesJournal of Neurochemistry, Volume 170, Issue 1, January 2026.
Given the absence of curative treatments for neurodegenerative diseases, early detection and therapeutic intervention are critical to slowing disease progression. The last decade has seen accumulating evidence for microRNA dysregulation in circulating extracellular vesicles (EVs); however, assessing reproducibility between studies remains challenging ...
Aliyah Zaman   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy